title: Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
authors.affiliation: Monroe College of Pharmacy, University of Louisiana, 1725 Claiborne Avenue, Shreveport, LA 71103, USA. eperr5@lsuhsc.edu
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Perry
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D004348:Drug Labeling; D005820:Genetic Testing; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D011110:Polymorphism, Genetic; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine